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Background: Raltegravir is the first integrase inhibitor approved for treatment of HIV-infected 
patients harboring multiresistant viruses.
Methods: From a Danish population-based nationwide cohort of HIV patients we identified 
the individuals who initiated a salvage regimen including raltegravir and a matched cohort of 
HIV-infected patients initiating HAART for the first time. We compared these two cohorts for   
virological suppression, gain in CD4 count, and time to first change of initial regimen.
Results: We identified 32 raltegravir patients and 64 HIV patients who initiated HAART for the 
first time in the period 1 January 2006 to 1 July 2009. The virological and immunological responses 
in the raltegravir patients were comparable to those seen in the control cohort. No patients in the 
two cohorts died and no patients terminated raltegravir treatment in the observation period. Time 
to first change of initial regimen was considerably shorter for HAART-naïve patients.
Conclusion: We conclude that salvage regimens including raltegravir have high effectiveness 
in the everyday clinical setting. The effectiveness of the regimens is comparable to that observed 
for patients initiating HAART for the first time. The risk of change in the salvage regimens 
after initiation of raltegravir is low.
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Introduction
Highly active antiretroviral therapy (HAART) was introduced more than a decade ago 
and the therapy has decreased mortality and morbidity of HIV patients dramatically.1,2 
The first HAART regimens were composed of nucleoside reverse transcriptase inhibitors 
(NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), and protease 
inhibitors (PIs). Especially the early regimens carried a substantial risk of failure and 
subsequent development of resistance to the three drug classes.3 Thus there has been 
a need for development of new drugs with activity against viruses resistant to the 
classical HAART regimens either as new drugs from the old classes without (or with 
limited) cross resistance to the older compounds or drugs from new classes with new 
antiretroviral mechanisms. The optimal choice for salvage therapy for HIV-infected 
patients has been shown to require at least 2, and preferably 3, fully active drugs.4–6 
Until recently, salvage regimens used to treat patients harboring multidrug-resistant 
HIV generally included only one new agent from the classic drug classes added to 
an optimized background therapy which did not contain any fully active agents. This 
approach, conditioned by limited drug options, put patients at high risk of virological 
failure and resistance to the new agent, as well as to other agents in the same drug 
classes.7–9 A breakthrough has been the recent development of integrase inhibitors, Clinical Epidemiology 2010:2 146
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which is a new class of antiretroviral drugs.10 One of these 
drugs – raltegravir – has demonstrated its activity in patients 
with virological failure on classical antiretroviral drugs.11 
In the BENCHMARK randomized clinical trials, which were 
conducted in HIV-infected patients with limited treatment 
options, 62% of patients taking raltegravir plus optimized 
background treatment achieved plasma HIV RNA levels 50 
copies/mL at week 48.11 Although the drug – often used 
together with other new drugs – has been proved effective in 
clinical trials and recently in ‘real life’ clinical settings,12–14 the 
long-term efficacy is not described and the effect compared to 
treatment in HAART-naïve patients remains to be established. 
In a nationwide cohort of HIV-infected patients, we identified 
the patients, who initiated raltegravir due to virological failure 
and a matched control cohort of patients initiating HAART for 
the first time. We compared these two cohorts for virological 
suppression, gain in CD4 cell count, and time to first change 
of initial regimen.
Method
Setting
Denmark had a population of 5.5 million as of 31 December 
2008, with an estimated HIV prevalence of approximately 
0.07% in the adult population.15,16 Patients with HIV infec-
tion are treated in one of the country’s 8 specialized medical 
centers, where they are seen on an outpatient basis at intended 
intervals of 12 weeks. Antiretroviral treatment is provided 
free of charge to all HIV-infected residents of Denmark.
Data sources
The Danish HIV Cohort study (DHCS) is a population-
based prospective nationwide cohort study of all HIV-
infected individuals 16 years or older at diagnosis and who 
are treated at Danish HIV centers after 1 January 1995.17 
Patients are consecutively enrolled, and multiple registra-
tions are avoided through the use of a unique 10-digit civil 
registration number assigned to all individuals in Denmark 
at birth or upon immigration. Data are updated yearly 
and include demographics, date of HIV infection, AIDS-
defining events, date and cause of death, and antiretroviral 
treatment. The national criteria for initiating HAART have 
been described previously.18 CD4 cell counts and HIV-RNA 
measurements are extracted electronically from laboratory 
data files. On 31 December 2008 the cohort included 5206 
Danish HIV-infected residents.
Sequences containing the reverse transcriptase and the 
protease gene (1300 base pairs) were obtained through 
population-based sequencing using ViroseqTM HIV-1 
genotyping System v.2 (Abbott Diagnostics, Foster City, 
USA) and collected from the Danish HIV Sequence 
Database.19 All sequences were obtained from plasma 
samples collected before start of raltegravir. Resistance 
mutations against all the approved NRTI, NNRTI, and 
PI drugs were identified and classified using the Stanford 
Genotypic Resistance Interpretation Algorithm (version 
6.0.7; HIV Drug Resistance Database, Stanford, CA, 
USA).20
Study populations
Raltegravir cohort patients: From DHCS we included all 
HIV-1 positive patients, who 1) started raltegravir after 
1 January 2006 and before 1 July 2009, 2) had been treated 
with HAART previously, 3) had at least 2 viral load (VL) 
tests done prior to initiation of raltegravir treatment, 4) had 
virological failure prior to start of raltegravir and, 5) did 
not participate in randomized clinical trials on raltegravir. 
Virological failure was defined as VL 500 copies/mL in 
the two latest VL tests prior to raltegravir initiation while 
on HAART treatment.
Control cohort patients: From DHCS we identified a 
control cohort of HIV-infected patients who started HAART 
for the first time after 1 January 2006 and before 1 July 2009. 
From this population we extracted 2 control patients for each 
raltegravir patient, each matched by gender, race (Caucasian, 
Black, and other), route of HIV infection (homosexual, 
heterosexual, injection drug user [IDU], and other) and 
age (intervals of 20 years, 20 to 30 years, 30 to 40 years, 
50 years). Due to lack of controls, matching with younger 
patients was allowed for 1 raltegravir patient of African 
origin, with homosexual HIV transmission, and older than 
50 years.
Statistics
Demographics and characteristics were computed for the 
raltegravir and control cohort, as were characteristics of 
treatment regimens used prior to raltegravir initiation and 
with raltegravir.
Index date was defined as date of first initiation of 
raltegravir or of HAART in the raltegravir and control 
cohort, respectively. We used Kaplan–Meier analysis to 
describe time to first change in antiretroviral regime and in 
these analysis, time was calculated from index date to date 
of last outpatient visit, 1 July 2009 or date of first change in 
antiretroviral regime, whichever came first. In other analysis 
time was calculated from index date to 1 July 2009, date of 
immigration or date of death, whichever came first.Clinical Epidemiology 2010:2 147
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Using a previously described method we grouped all 
CD4 cell measurements and VL tests in the observation 
period in 12-week intervals and calculated the propor-
tion of VL tests 51 copies/mL and the median CD4 cell 
count from 96 weeks before to 72 weeks after index date.17 
Differences in median CD4 cell count between the two 
cohorts at index date and after 72 weeks were evaluated by 
Fisher’s exact test. We evaluated effect on CD4 cell count 
from baseline to week 48 and 72.
The study was approved by the Danish Data Protection 
Agency. The study is registered with ClinicalTrials.gov 
(Identifier: NCT01061957). SPSS statistical software, 
Version 15.0 (Norusis; SPSS Inc, Chicago, Illinois, USA) 
and R software, version 2.8.1, was used for data analysis.
Results
From DHCS we identified 32 patients who started a salvage 
regimen including raltegravir and a control cohort of 64 
patients naïve to antiretroviral drugs who started HAART 
with 50.2 and 142.8 years of observation, respectively. No 
raltegravir or control patients were lost to follow up. As seen 
from Table 1 the raltegravir patients and the control patients 
were well matched with respect to age, gender, race and 
route of HIV infection, but due to the differences in inclu-
sion criteria differed in time from HIV diagnosis to index 
date, AIDS-defining events prior to index date, and VL and 
CD4 cell count at index date. The raltegravir cohort had been 
treated with several different antiretroviral regimens and a 
major fraction was on a regimen including a boosted protease 
inhibitor prior to the start of raltegravir (Table 2). Ten (31.3%) 
of the raltegravir patients were treated with zidovudin prior 
to start of raltegravir compared with 3 (9.4%) after start of 
raltegravir (Appendix 1).
All raltegravir patients had primary resistance muta-
tions against 1 or more drug classes, 32 (100%) had pri-
mary resistance mutations against 2 or more drug classes 
and 26 (81.3%) had primary resistance mutations against 
3 classes. NRTI resistance mutations were found in 32 
(100%) raltegravir patients, 29 (90.1%) had NNRTI resis-
tance mutations, and 29 (90.1%) had primary PI resistance 
mutations.
The optimized background salvage regimens started at 
the time of raltegravir initiation included treatment with 
etravirine in 30% of the raltegravir patients and darunavir in 
almost 90% of the patients (84.4% initiated boosted darunavir 
at the same time as raltegravir) (Table 3). Two (6.3%) of the 
patients did not receive any NRTI.
No raltegravir or control patients died in the observation 
period and an AIDS-defining event occurred in 1 (3.1%) and 
5 (7.8%) patients in the raltegravir cohort and control cohort, 
respectively. After the initiation of raltegravir or HAART, the 
majority of the two cohorts obtained a VL 50 copies/mL after 
72 weeks of treatment (Figure 1). All raltegravir patients achieved 
virological suppression in the observation period. Notably the 
Table 1 Characteristics and demographics of patients treated with raltegravir and a control population naïve to HAART
Characteristics Raltegravir patients N = 32 Controls N = 64
Male gender 21 (65.6%) 42 (65.6%)
Age at time of index date, median (IQR), years 50.8 (42.5–55.1) 47.3 (40.5–56.3)
Race
  Caucasian 23 (71.9%) 46 (71.9%)
  Black 7 (21.9%) 14 (21.9%)
  Other 2 (6.2%) 4 (6.2%)
Route of HIV infection
  Men who have sex with men 15 (46.9%) 30 (46.9%)
  Heterosexually infected 17 (53.1%) 34 (53.1%)
  Injection drug user None None
  Other None None
Diagnosed with HIV before 1 January 1995 9 (28.1%) 5 (7.8%)
CD4 cell count at index date, median (IQR), cells/µL 280 (60–291) 221 (181–472)
Viral load at index date, median (IQR), log10 copies/mL 2.45 (1.60–3.16) 4.40 (3.24–5.46)
Time from HIV diagnosis to index date, median (IQR), years 15.3 (12.5–18.8) 0.2 (0.1–3.4)
Time from HAART start to index date, median (IQR), years 10.7 (10.0–11.3) –
One or more AIDS-defining events prior to index date 14 (43.8%) 11 (17.2%)
Abbreviations: IQR, interquartile range.Clinical Epidemiology 2010:2 148
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virological response was almost equivalent in the raltegravir and 
the control cohorts at week 72 (100% vs 83.3%, respectively).
The raltegravir patients had a higher median CD4 cell 
count at index date than the control cohort (280 cells/µL 
[IQR, interquartile range; 60–291] vs 221 cells/µL [IQR; 
181–472], P = 0.02), (Figure 2). Both cohorts had a strong 
CD4 response to raltegravir and HAART initiation, respec-
tively. The median CD4 cell count increase from index 
date to week 48 was 180 cells/µL (IQR; 40–244) in the 
raltegravir cohort and 160 cells/µL (IQR; 81–239) in the 
control cohort. After 72 weeks of treatment the raltegravir 
cohort continued to have a higher CD4 cell count compared 
with the control patients (558 cells/µL [IQR; 420–656] 
vs 399 cells/µL [IQR; 286–529], P = 0.01). The increase 
in median CD4 cell count from baseline to week 72 was 
270 cells/µL (IQR; 146–390) in the raltegravir cohort and 
183 cells/µL (IQR; 98–265) in the control cohort.
None of the raltegravir patients stopped raltegravir in the 
study period. Figure 3 illustrates time to first change in the 
HAART regimens in the two cohorts. Almost two thirds of 
the raltegravir patients were on the initial salvage regimen 
after 1 year compared with less than 50% of the patients in 
the control cohort.
Discussion
In an observational, nationwide and population-based study 
we found a high effectiveness of salvage regimens includ-
ing raltegravir. The clinical progression, immunological 
and virological responses were comparable to those seen 
in a matched cohort of HIV-infected patients initiating 
HAART for the first time. The major strengths of the study 
are its nationwide population-based design, combined with 
complete follow-up.
The impact of the raltegravir regimens on VL was 
comparable to that seen in patients initiating HAART for 
the first time. Compared to other studies we observed a 
slightly lower initial virological response in the raltegravir 
patients,12,14 but after 72 weeks all patients were virologically 
suppressed. As almost all of the patients initiated boosted 
darunavir as part of salvage regimens, we were not able 
Table 2 Characteristics of HAART regimens used prior to first 
raltegravir regimen
Number of all NRTIs, NNRTIs, and PIs used  
prior to first raltegravir regimen
Median (IQR)
NRTI 5 (5–7)
NNRTI 1 (1–2)
PI 4 (4–5)
Drugs included in the last HAART regimen  
prior to first raltegravir initiation
N (%)
NRTI 31 (96.9)
  1 NRTI 2 (6.3)
  2 NRTI 22 (68.8)
  3 NRTI 7 (21.9)
NNRTI 4 (12.5)
PI 32 (100)
  Boosted PI 28 (87.5)
  Non-boosted PI 4 (12.5)
Abbreviations: IQR, interquartile range; NRTIs, nucleoside reverse transcriptase 
inhibitors; NNRTIs, non-nucleoside reverse transcriptase inhibitors; PIs, protease 
inhibitors.
Table 3 Antiretroviral drugs in first raltegravir regimen
Antiretroviral drugs N (%)
NRTI 24 (75.0)
  1 NRTI 3 (9.4)
  2 NRTI 17 (53.1)
  3 NRTI 4 (12.5)
NNRTI 14 (43.8)
  Etravirine 12 (37.5)
Boosted PI 30 (93.8)
  Darunavir 28 (87.5)
Non-boosted PI 2 (6.7)
  CCR5 inhibitor (maraviroc) 3 (9.4)
  Fusion inhibitor (enfuvirtide) 1 (3.1)
Abbreviations: NRTIs, nucleoside reverse transcriptase inhibitors; NNRTIs, non-
nucleoside reverse transcriptase inhibitors; PIs, protease inhibitors.
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Figure 1 Fraction of viral load (VL) tests below 51 copies/mL in 12 weeks intervals 
for the raltegravir cohort (full line) and the control cohort (broken line). Week 0 is 
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to distinguish between the raltegravir and the darunavir 
effects. The strong antiretroviral effect of darunavir has 
been shown in a study by Arribas et al who demonstrated 
that the antiretroviral effect of monotherapy with boosted 
darunavir was comparable to that obtained with triple combi-
nation therapy.21 Further, the SWITCHMRK study, in which 
raltegravir underperformed compared to boosted lopinavir 
in patients with regimens primarily dependent on these two 
drugs, indicates the importance of an optimized background 
regimen including a boosted protease inhibitor.11,22 In the 
present study only one third of the patients used etravirine 
as this drug was not available in Denmark until the last half 
of the study period.
Surprisingly, the initial CD4 cell recovery in the 
raltegravir cohort was higher than that of the controls and that 
found in the TRIO trial.12 At week 72 the raltegravir cohort 
exceeded the control cohort, rising to a median CD4 cell 
count above 500 cells/µL. A similar increase was observed 
in perinatally infected adolescents.23 If a previous drop in 
the CD4 count had induced the change to the raltegravir 
regimens, regression towards the mean could partly explain 
a subsequent increase in CD4 count. However, the course 
of the CD4 cell count in the observation period prior to 
introduction of the salvage regimen does not suggest such a 
phenomenon. It may be hypothesized that patients surviving 
despite years of virological failure may have a greater CD4 
generating capacity and the increase in CD4 count therefore 
may be a healthy survivor phenomenon. The discontinuation 
of zidovudine in a large proportion of the patients prior to 
salvage therapy could partly explain this unprecedented large 
CD4 increase.
Time to change of the initial raltegravir regimen was 
considerably longer than time to change in initial HAART 
regimen in the control cohort, thus supporting the findings 
of Willig et al.24 We, however, compared regimens given 
in two very different situations. The salvage patients were 
facing potential progression of the underlying infection 
due to limited treatment options, thus the patients and 
their healthcare providers presumably accepted far greater 
side effects before changing regimens compared to the 
HAART-naïve patients. Still, our results indicate a high 
tolerance of raltegravir.
The mortality in HIV patients on HAART is low and 
may approach that of the background cohort.1 In accordance 
with this we observed no death in the two cohorts and no 
increased risk of AIDS-defining illness in the raltegravir 
group. However, in order to evaluate clinical endpoints a 
substantially larger study population and longer observation 
period are needed.
We conclude that salvage regimens including raltegravir 
are effective not only in clinical trials, but also have 
high effectiveness in the everyday clinical setting. The 
effectiveness of the regimens is comparable to that observed 
for patients initiating HAART for the first time. The risk that 
raltegravir is stopped prematurely or the salvage regimens 
are changed after initiation is low.
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Appendix 1 HAART regimen in the raltegravir cohort prior to and after start of raltegravir
Patient Pre-raltegravir treatment On-raltegravir treatment
#1 ZDV, 3CT, ABC, RTV, DRV ZDV, 3CT,ABC, RTV, DRV, RAL
#2 ZDV, 3CT, RTV FTC, TDF, DRV, NVP, ETV, RAL
#3 ZDV, 3CT, RTV 3CT, ABC, RTV, DRV, ETV, RAL
#4 TDF, RTV, EFV RTV,DRV, ETV, RAL
#5 ZDV, TDF, ATV FTC, TDF, ATV, RAL
#6 3CT, ABC, TDF, RTV, ATV RTV, DRV, ETV, RAL
#7 3CT, ABC, RTV, ATV, EFV FTC, TDF, RTV, DRV, RAL
#8 3CT, ABC, RTV, ATV FTC, TDF, RTV, DRV, RAL
#9 RTV, LPV, EFV FTC, TDF, RAL
#10 3CT, ABC, RTV, TPV, t20 RTV, DRV, RAL, MVC
#11 ZDV, 3CT, TDF, RTV, TPV FTC, TDF, RTV, DRV, ETV, RAL
#12 3CT, ABC, RTV, ATV RTV, DRV, ETV, RAL
#13 ZDV, 3CT, TDF, RTV, TPV FTC, TDF, RTV, DRV, RAL
#14 ZDV, 3CT, ATV ABC, TDF, DRV, RAL
#15 D4T, ABC, TDF, SQV, RTV RTV, DRV, ETV, RAL
#16 3CT, DDI, TDF, RTV, TPV FTC, DDI, TDF, RTV, DRV, RAL, T20
#17 3CT, ABC, RTV TDF, RTV, RAL
#18 DDI, TDF, RTV, AMP RTV, DRV, RAL, ETV
#19 3CT, D4T, DDI, RTV, IDV, ZDV,3CT, ABC, RTV, ETV, RAL
#20 DDI, ABC, RTV RTV, DRV, RAL
#21 3CT, D4T, RTV 3CT, DDI, RTV, DRV, RAL
#22 3CT, D4T, RTV FTC, TDF, DRV, ETV, RAL
#23 DDI, ABC, RTV DRV, EFV, ETV, RAL
#24 DDI, ABC, ATV FTC, TDF, RTV, DRV, RAL
#25 FTC, TDF, RTV FTC, RTV, DRV, RAL
#26 DDI, ABC, RTV, ATV FTC, TDF, RTV, DRV, RAL
#27 ABC, RTV 3CT, ABC, RTV, DRV, RAL
#28 ZDV, TDF, SQV, RTV ZDV, FTC, TDF, SQV, RTV, DRV, RAL, MVC
#29 ABC, TDF, RTV, ABC, TDF, RTV, DRV, RAL
#30 ABC, TDF, RTV, TPV 3CT, ABC, RTV, DRV, ETV, RAL
#31 ZDV, 3CT, RTV, EFV FTC, TDF, DRV, RAL, MVC
#32 ZDV, DDI, RTV, IDV TDF, RTV, DRV, NVP, RAL
Abbreviations: TDF, tenofovir; RTV, ritonavir; SQV, saquinavir; FTC, emtricitabine; DRV, darunavir; DDI, didanosine;  ABC, abacavir; 3TC, lamivudine; D4T, stavudine; LPV, lopinavir; 
EFV, efavirenz; TPV, tipranavir; FPV, fosamprenavir; NVP, nevirapine; ATV, atazanavir; IDV, crixivan; ZDV, zidovudine; ETV, etravirine; MVC, maraviroc;  AMP, amprenavir.